Company Profile For Vernalis PLC

Vernalis plc is a development stage pharmaceutical company engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. It focuses both in de novo fragment and structure-based drug discovery, and pre-clinical and clinical development. The Company has seven product candidates in clinical development (two of which are partnered), two programmes in pre-clinical (one with a partner) and other research programmes. It has one marketed product and a pipeline of clinical drug candidates and research programmes. Its product pipeline includes V3381, V1512, V10153, V2006 (BIIB014), V85546, V24343, NVP-AUY922, Hsp90 inhib. (Oral), FAAH V158866 and Checkpoint Kinase 1 (Chk1). On July 1, 2008, the Company announced that it had completed the sale of Apokyn and Vernalis Pharmaceuticals Inc, its United States commercial operations, to Ipsen SA.

BRIEF: For the six months ended 30 June 2009, Vernalis plc's revenues decreased 88% to £5.7M. Net loss from continuing operations totaled £5.3M vs. an income of £16.4M. Revenues reflects a decrease in income from Company's products and services. Net loss reflects an increase in finance expenses. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders.